Related references
Note: Only part of the references are listed.Genetics of Opisthorchis viverrini-related cholangiocarcinoma
Apinya Jusakul et al.
CURRENT OPINION IN GASTROENTEROLOGY (2015)
Molecular landscape of pancreatic cancer: implications for current clinical trials
Gregory M. Heestand et al.
ONCOTARGET (2015)
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
J. W. Valle et al.
ANNALS OF ONCOLOGY (2014)
Emerging drugs for biliary cancer
Takuji Okusaka et al.
EXPERT OPINION ON EMERGING DRUGS (2014)
Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors
Brian A. Costello et al.
INVESTIGATIONAL NEW DRUGS (2014)
New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
Jeffrey S. Ross et al.
ONCOLOGIST (2014)
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Chaitanya R. Churi et al.
PLOS ONE (2014)
Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities
Sumera Rizvi et al.
SEMINARS IN LIVER DISEASE (2014)
Palliation: Treating Patients with Inoperable Biliary Tract and Primary Liver Tumors
Albert Amini et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Epidemiology and Risk Factors of Biliary Tract and Primary Liver Tumors
Mathew M. Augustine et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups
Michele Simbolo et al.
ONCOTARGET (2014)
The NF1 gene revisited - from bench to bedside
Yoon-Sim Yap et al.
ONCOTARGET (2014)
Histological Characterization of Biliary Intraepithelial Neoplasia with respect to Pancreatic Intraepithelial Neoplasia
Yasunori Sato et al.
INTERNATIONAL JOURNAL OF HEPATOLOGY (2014)
Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions
Jesse S. Voss et al.
HUMAN PATHOLOGY (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers
Waraporn Chan-on et al.
NATURE GENETICS (2013)
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Yuchen Jiao et al.
NATURE GENETICS (2013)
KrasG12D and p53 Mutation Cause Primary intrahepatic Cholangiocarcinoma
Michael R. O'Dell et al.
CANCER RESEARCH (2012)
Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors
Jesper B. Andersen et al.
GASTROENTEROLOGY (2012)
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
Anthony B. El-Khoueiry et al.
INVESTIGATIONAL NEW DRUGS (2012)
The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas
Dakeun Lee et al.
MODERN PATHOLOGY (2012)
Exome sequencing of liver fluke-associated cholangiocarcinoma
Choon Kiat Ong et al.
NATURE GENETICS (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Darrell R. Borger et al.
ONCOLOGIST (2012)
HER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib
Joshua Peck et al.
ONCOLOGY (2012)
KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients
Rui Feng Xu et al.
BIOMEDICINE & PHARMACOTHERAPY (2011)
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
Vikram Deshpande et al.
BMC CANCER (2011)
Molecular mechanisms of bile duct development
Yiwei Zong et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2011)
Targeted therapies for breast cancer
Michaele J. Higgins et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Tanios Bekaii-Saab et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
Jeffrey J. Wallin et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
C. Bengala et al.
BRITISH JOURNAL OF CANCER (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: Is the biliary tract an incomplete pancreas?
Yasuni Nakanuma
PATHOLOGY INTERNATIONAL (2010)
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramesh K. Ramanathan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
The Expression of Phospho-AKT, Phospho-mTOR, and PTEN in Extrahepatic Cholangiocarcinoma
Joon-Yong Chung et al.
CLINICAL CANCER RESEARCH (2009)
Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan
Shuichi Miyakawa et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY (2009)
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
D. Yoshikawa et al.
BRITISH JOURNAL OF CANCER (2008)
Trends in survival after surgery for cholangiocarcinoma: A 30-year population-based SEER database analysis
Hari Nathan et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2007)
Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients
H. J. Kim et al.
ANNALS OF ONCOLOGY (2007)
Current surgical treatment for bile duct cancer
Yasuji Seyama et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy
Melanie B. Thomas
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan
Iwao Ikai et al.
HEPATOLOGY RESEARCH (2007)
Cholangiocarcinoma: Modern advances in understanding a deadly old disease
Harmeet Malhi et al.
JOURNAL OF HEPATOLOGY (2006)
Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas
Yoh Zen et al.
HEPATOLOGY (2006)
Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma
F Leone et al.
CLINICAL CANCER RESEARCH (2006)
Analysis of extrahepatic bile duct carcinomas according to the new American Joint Committee on Cancer staging system focused on tumor classification problems in 222 patients
SM Hong et al.
CANCER (2005)
Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers
K Nakazawa et al.
JOURNAL OF PATHOLOGY (2005)
The epidemiology of cholangiocarcinoma
Y Shaib et al.
SEMINARS IN LIVER DISEASE (2004)
Share Paper
